Floatz logo

Tarloxotinib

NRG1 Fusion

Rain Oncology IncPhase 2Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the NRG1 Fusion cohort.

Asset / SponsorPhaseRating
Zenocutuzumab
Partner Therapeutics, Inc.
Phase 2CCC

Same molecule, other indications

Tarloxotinib is also rated in:

NSCLCDormant
D
Indicative ·
30 / 100
View asset →
non-small cell lung carcinomaDormant
D
Indicative ·
30 / 100
View asset →
EGFR Exon 20 Insertion MutationDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →